

Table 1 Suppl.: Change from baseline to week 24 in number of swollen (SJC) and tender joints (TJC) and PGA of disease activity on the VAS in patients with different DAS28 baseline in correlation with DAS28 based disease activity. Compared to the acute phase response, the relative effect on the SJC and TJC in patients reaching DAS28 remission after 24 weeks was even more pronounced compared with the decrease in APR in these patients. Of note, in patients with a high DAS28 of > 5.1 at baseline, the relative effect on the swollen and tender joints was even more prominently than in patients with a DAS < 5.1. PGA and PhGA of disease activity also improved significantly after the treatment with TCZ, the ESR was within normal limits in virtually all patients in both DAS28 groups. The missing 22 patients had a DAS28 < 4.1 or a missing (DAS n = 12) at baseline (due to missing ESR).

	DAS28 4.1 – 5.1 (n=47)		DAS28 > 5.1 (n=217)	
	Absolute value (Mean + SD)	Relative difference to baseline (%) [Mean + SD]	Absolute value (Mean + SD)	Relative difference to baseline (%) [Mean + SD]
SJC				
baseline	4.4 ± 2.7		11.0 ± 5.1	
week 24	2.0 ± 3.2	-48.6± 72.4	2.8 ± 3.7	-72.3 ± 37.6
TJC				
baseline	5.8 ± 2.9		14.5 ± 6.0	
week 24	2.1 ± 2.6	-55.4± 61.5	4.8 ± 6.3	-68.1± 40.4
Patients assessment of disease assessment (VAS)				
baseline	52.8 ±18.5		65.3±19.4	
week 24	25.4 ± 22.1	-43.9 ± 56.2	27.3 ± 25.9	-53.0 ± 55.7
Physicians assessment of disease assessment (VAS)				
baseline	54.9 ± 16.7		65.6 ± 17.3	
week 24	20.5 ± 21.3	-57.5 ± 54.8	17.9 ± 19.3	-62.2 ± 170.3
ESR				
ESR baseline	27,9 ± 16,9		40,3 ± 22,4	
ESR week 24	5,6 ± 5,6	-73,3 ± 26,6	7,6 ± 10,5	-72,4 ± 88,7